Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2021 Mar 8;15(3):e0009213. doi: 10.1371/journal.pntd.0009213

Sporadic outbreaks of crimean-congo haemorrhagic fever in Uganda, July 2018-January 2019

Bernadette Basuta Mirembe 1,*, Angella Musewa 1, Daniel Kadobera 1, Esther Kisaakye 1, Doreen Birungi 1, Daniel Eurien 1, Luke Nyakarahuka 2,3, Stephen Balinandi 2,3, Alex Tumusiime 2, Jackson Kyondo 2, Sophia Mbula Mulei 2, Jimmy Baluku 2, Benon Kwesiga 1, Steven Ndugwa Kabwama 1, Bao-Ping Zhu 4,5, Julie R Harris 4,5, Julius Julian Lutwama 2, Alex Riolexus Ario 1,6
Editor: Brian Bird7
PMCID: PMC7971858  PMID: 33684124

Abstract

Introduction

Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne, zoonotic viral disease that causes haemorrhagic symptoms. Despite having eight confirmed outbreaks between 2013 and 2017, all within Uganda’s ‘cattle corridor’, no targeted tick control programs exist in Uganda to prevent disease. During a seven-month-period from July 2018-January 2019, the Ministry of Health confirmed multiple independent CCHF outbreaks. We investigated to identify risk factors and recommend interventions to prevent future outbreaks.

Methods

We defined a confirmed case as sudden onset of fever (≥37.5°C) with ≥4 of the following signs and symptoms: anorexia, vomiting, diarrhoea, headache, abdominal pain, joint pain, or sudden unexplained bleeding in a resident of the affected districts who tested positive for Crimean-Congo haemorrhagic fever virus (CCHFv) by RT-PCR from 1 July 2018–30 January 2019. We reviewed medical records and performed active case-finding. We conducted a case-control study and compared exposures of case-patients with age-, sex-, and sub-county-matched control-persons (1:4).

Results

We identified 14 confirmed cases (64% males) with five deaths (case-fatality rate: 36%) from 11 districts in western and central region. Of these, eight (73%) case-patients resided in Uganda’s ‘cattle corridor’. One outbreak involved two case-patients and the remainder involved one. All case-patients had fever and 93% had unexplained bleeding. Case-patients were aged 6–36 years, with persons aged 20–44 years more affected (AR: 7.2/1,000,000) than persons ≤19 years (2.0/1,000,000), p = 0.015. Most (93%) case-patients had contact with livestock ≤2 weeks before symptom onset. Twelve (86%) lived <1 km from grazing fields compared with 27 (48%) controls (ORM-H = 18, 95% CI = 3.2-∞) and 10 (71%) of 14 case-patients found ticks attached to their bodies ≤2 weeks before symptom onset, compared to 15 (27%) of 56 control-persons (ORM-H = 9.3, 95%CI = 1.9–46).

Conclusions

CCHF outbreaks occurred sporadically during 2018–2019, both within and outside ‘cattle corridor’ districts of Uganda. Most cases were associated with tick exposure. The Ministry of Health should partner with the Ministry of Agriculture, Animal Industry and Fisheries to develop joint nationwide tick control programs and strategies with shared responsibilities through a One Health approach.

Author summary

Uganda has had multiple Crimean-Congo haemorrhagic fever outbreaks since 2013 when the first outbreak was confirmed. Tick exposure has been identified as the major risk factor by our study and this finding was similar with other studies done during outbreaks in Uganda. However, Uganda still lacks national tick control guidelines and indiscriminate use of acaricides (pesticides specially for ticks) has been observed widely. This has been cited to influence increased tick resistance to acaricides. Our study might not indicate whether tick resistance to acaricides has increased tick populations in Uganda however it is imperative that tick control is considered in efforts of prevention and control of CCHF outbreaks. We therefore recommend improved tick control in Uganda through national regulations on acaricide distribution and use, development of strategies to reduce tick resistance to acaricides in the country, and more community-based engagement of tick control in livestock management.

Introduction

Crimean-Congo haemorrhagic fever (CCHF) is a viral haemorrhagic fever (VHF) caused by a virus from the family Bunyaviridae genus Nairovirus. The disease is endemic in Africa and is one of the notifiable zoonotic diseases in Uganda [1]. Ticks that feed on infected livestock and subsequently feed on humans can transmit the virus between species, but contact with infectious blood or bodily secretions may also transmit the virus between livestock and humans, or from one human to another [2]. Various domestic livestock and wildlife act as amplifying hosts for the virus, but unlike humans, infected livestock do not exhibit clinical symptoms [3,4]. Globally, Crimean-Congo haemorrhagic fever virus (CCHFv) is found in Africa, Asia, and Europe; within these areas, shrub and grassland cover, which is favourable for ticks, is an important predictor of virus distribution [5]. The geographic distribution of the virus correlates with that of ticks belonging to the genus Hyalomma, which are the principal vectors. However, Rhipicephalus and Dermacentor ticks are also able to carry CCHFv hence can potentially be transmitted [6]. In a study in Iran, 4.6% infection rate was found in Hyalomma genus and 0.7% in Rhipicephalus sanguineus species; and both thrive in Uganda [7].

The incubation period for CCHFv in humans mainly depends on viral dose and route of infection [8,9]. Incubation is typically 1–9 days following a tick bite, and 5–13 days following contact with infectious fluids [1]. Humans infected with CCHFv can transmit the virus to other persons via blood or other bodily secretions following symptom onset [10]. Symptoms include sudden high-grade fever, headache, vomiting, back pain, joint pain, and stomach pain. Haemorrhaging may occur in later stages of the illness [1]. Between 10% and 40% of patients die of the disease. Real-time polymerase chain reaction (RT-PCR) is used for disease confirmation in the acute phase, whereas serological tests are used in the convalescent phase [4]. Case management is primarily through supportive treatment, although ribavirin treatment may be beneficial [4].

Uganda has had a VHF surveillance system since 2010. The program has more than 20 sentinel surveillance sites and receives samples for testing from all over Uganda as well as neighbouring countries, such as South Sudan and Rwanda. This increased surveillance has led to multiple confirmations of CCHF outbreaks–categorized as one or more cases of CCHF–in the intervening years [11]. During 2013–2017, Uganda documented eight confirmed CCHF outbreaks, all within the ‘cattle corridor’ but in geographically distinct districts. The ‘cattle corridor’ illustrated in Fig 1 is an area stretching from southwestern to northeastern Uganda and is dominated by pastoral rangelands. The first CCHF outbreak documented in the VHF surveillance system occurred in 2013 in Agago District, with three case-patients. During the next five years, fewer than 10 cases were reported in multiple independent outbreaks in Wakiso, Nakaseke, Kiboga, Luweero, and Mubende Districts. Notes from the field published after a CCHF outbreak in central Uganda found exposure to ticks as a risk factor for infection [12].

Fig 1. Distribution of Crimean-Congo haemorrhagic fever case-patients confirmed between July 2018 and January 2019, highlighting the ‘cattle corridor’ and the sequence of symptom onset of the case-patients.

Fig 1

In July 2018, the Uganda Virus Research Institute (UVRI) (the national reference laboratory for VHF diagnosis in Uganda) reported two PCR-confirmed CCHF cases from Isingiro District. Over the next seven months, nearly a dozen CCHF cases were confirmed in various districts, raising concern at the Ministry of Health about reasons for possible increase in frequency and geographical distribution of the disease. In July 2018, we began an investigation to determine the scope of the outbreaks during mid-2018 to early-2019, and to identify risk factors for disease.

Methods

Ethics statement

This investigation was in response to public health emergencies i.e. CCHF outbreaks and was therefore determined to be non-research. The Ministry of Health Uganda through the Office of the Director General of Health Services gave the directive and approval to investigate this outbreak. The Office of the Associate Director for Science, Centers for Global Health, CDC also determined that this activity was not human subject research, and its primary intent was public health practice or a disease control activity (specifically, epidemic or endemic disease control activity). We obtained verbal informed consent from case-patients during this investigation and other interviewed community members that were above 18 years. For participants below 18 years of age, we sought verbal consent from their parents or guardians and assent from the minors. We ensured confidentiality by conducting interviews in privacy ensuring that no one could follow proceedings of the interview. The questionnaires were kept under lock and key to avoid disclosure of personal information of the respondents to members who were not part of the investigation.

Case definition and case-finding

We defined a suspected case as sudden onset of fever (≥37.5°C) with ≥4 of the following signs and symptoms: anorexia, vomiting, diarrhoea, headache, abdominal pain, joint pain, or sudden onset of unexplained bleeding between 1 July 2018–30 January 2019 in a resident of one of the 11 affected districts. A confirmed case-patient was a suspected case-patient who tested positive for CCHFv by RT-PCR assay at UVRI. All laboratory procedures used in this laboratory for VHF diagnosis, including for CCHFv, have been previously published [13].

Descriptive epidemiology and hypothesis generation

Due to the nonspecific symptoms in early infection, ill persons are typically not formally investigated for CCHF without a positive test. Thus, following case confirmation, investigation teams were dispatched to the field to obtain further details. We conducted descriptive epidemiology to collect information on demographics, clinical characteristics, location, and timing of infection and associated potential exposures. We computed attack rates using the projected population estimates, based on the 2014 census for the 11 affected districts [14]. We used QGIS to draw maps using Uganda Bureau of Statistics (UBOS) shapefiles [15].

To identify potential risk factors, we interviewed eight case-patients using a modified standard WHO VHF case investigation form [16]. We interviewed the case-patients about their potential exposures between the minimum and maximum incubation periods for CCHF (effective exposure period of 1–14 days).

Case-control study

We conducted a case-control study that included 14 confirmed case-patients and four control-persons for each case-patient, matched by age (±10 years of case-patient age; for children <10 years, matched controls were +/-2 years of the case-patient age), sex, and sub-county. All control-persons were asymptomatic during the 14 days before the case-patient’s symptom onset. We collected data from both case-patients and control-persons on potential exposures during the effective exposure period (the two weeks before the case-patients’ onsets of fever) using a structured questionnaire. Exposures considered included contact with livestock, identification of ticks on the body, consumption of raw milk, and direct contact with body fluids of a human or animal.

We calculated attack rates using population statistics of the districts from Uganda Bureau of Statistics and significance was calculated using chi-square tests. We computed crude odds ratios using simple 2x2 analysis in Epi Info 7. To account for the matched case-control study design, we stratified the data by the case-control sets and computed the Mantel-Haenszel odds ratios (OR) and 95% confidence intervals (CI) in Epi Info 7. Exact conditional logistic regression was used with variables that failed to converge during stratification.

Results

Descriptive epidemiology of confirmed CCHF case-patients

Four hundred and nine suspected case-patients were identified in Uganda during July 2018 to January 2019 through the VHF surveillance system. Of these, 14 case-patients were confirmed CCHFv-positive in 13 separate outbreaks. Two case-patients were confirmed in each of Nakaseke, Isingiro and Kiryandongo districts. One case-patient was confirmed in each of Mukono, Ibanda, Rakai, Luweero, Masindi, Rukungiri, Kiruhura and Kabarole districts. Of the 11 affected districts, eight (73%) were in the ‘cattle corridor’ (Fig 1). Most of the case-patients (57%) lived in savannah grasslands, while 29% lived in highlands.

Five case-patients died (case-fatality rate = 36%). The most frequent symptoms were fever (100%), bleeding (93%), general body weakness (79%), and abdominal pain (71%).

The mean age of case-patients was 24 years (range: 6–36) and the most affected age group was 20–44 years (9/1,255,997; attack rate (AR) = 7.2/1,000,000) compared to persons ≤19 years (5/2,474,438; AR = 2.0/1,000,000). The difference was statistically significant with p = 0.015. The AR was nearly twice as high in males (10/2,063,605; AR = 4.4/1,000,000) as in females (5/2,109,141; AR = 2.4/1,000,000), although this difference was not statistically significant (p = 0.27). More than half (57%) of the case-patients were herdsmen; four (29%) had no reported interaction with livestock.

The first of the 14 case-patients had onset on 7 July 2018 in Isingiro District. Case-patient illnesses occurred subsequently in other districts with no identifiable pattern in time and place. The last case-patient in this investigation had illness onset on 16 January 2019 in Kiruhura District (Table 1 and Fig 1).

Table 1. Exposure information for case-patients with confirmed Crimean-Congo haemorrhagic fever during July 2018 to January 2019 in Western and Central Uganda.

Case-patient District Date of symptom onset Reported tick bite during 14 days before illness Suspected relevant exposure
1 Isingiro 7 July 2018 No • Lived near a kraal
• Tick-infested cattle recently relocated for pasture
2 Isingiro 12 July 2018 No • Likely infected by his wife, Case-Patient 1
• Lived near a kraal with tick-infested cattle
3 Mukono 18 August 2018 No • Lived in a semi-urban area
• No known contact with livestock
• Visited a mosque towards Eid al-Adha when livestock for slaughter had been brought
• Suspected to have been exposed during this time
4 Nakaseke 3 September 2018 Yes • Lived on a farm with livestock
• Livestock were not tick infested during the investigation
• Reported interaction with ticks, including biting ticks to kill them
5 Kiryandongo 15 September 2018 Yes • Lived with two tick-infested oxen (hard ticks seen)
6 Luweero 17 September 2018 Yes • Lived in an urban setting; owned tick-infested calf (hard ticks seen)
• Used to herd the calf
7 Rakai 17 September 2018 Yes • Household next to grazing field
• Used to sleep on the floor in a temporary house constructed from tarpaulin and twigs
• Reported tick infestation in beddings
8 Ibanda 3 October 2018 Yes • Slept in a semi-detached house with a room sharing a wall with a room that housed goats
• Reported that the church farm had received two tick-infested cattle in the two weeks before his onset
9 Kabarole 15 October 2018 Yes • The goats had no ticks at the time of our investigation
• Household was close to a grazing ground shared with distant neighbours
• Reported that she ‘always plucked ticks off her skin’ every morning
10 Nakaseke 20 October 2018 No • A child who lived on a farm with tick-infested livestock
11 Kiryandongo 23 October 2018 Yes • Lived in a household with a kraal for tick-infested cattle
• Reportedly interacted with the cattle and removed ticks on his body daily
12 Rukungiri 7 November 2018 No • Lived in highlands with goats
• No ticks identified on goats at time of visit
• Exposure still unclear
13 Masindi 26 December 2018 Yes • Visited his father’s farm before his onset
• Father reported the farm had tick-infested cattle
14 Kiruhura 16 January 2019 Yes • Lived on a property with >100 head of tick-infected cattle
• Reportedly had no interaction with livestock

The first two case-patients were a married couple from Isingiro District. The woman (wife) was the first case, she did not report a known tick bite, but lived near a kraal with tick-infested cattle. The second case-patient (husband) similarly did not report a tick bite but was exposed to the first case-patient (his wife) during his effective incubation period and had illness onset five days after his wife. This case-patient cared for his wife (who had haemorrhagic symptoms) during her illness and stayed with her in the hospital; his symptoms were mild (low-grade fever, general body weakness, sore throat and chest pain). Of the remaining cases, nine case-patients reported known tick bites (having found a tick on their bodies) during the 14 days before illness onset (Table 1) and three case-patients did not report tick bites (case-patients 3, 11, and 12), one lived in proximity to livestock infested with ticks at the time of our investigation, and one lived near goats, although they were not found to have ticks at the time of the study. However, one case-patient, from Mukono District, lived in a semi-urban area with no known contact with livestock. This case-patient visited a mosque where livestock were brought for Eid al-Adha (Festival of Sacrifice in Islam) two days before symptom onset, which might have provided a source of exposure. Unfortunately, the patient died, and further details of her exposure were unavailable.

From the descriptive analysis and environmental assessment, we hypothesised that having livestock nearby during the exposure period, living within a 1-km radius of grazing fields, having livestock within the household compound and having tick-infested livestock within the household compound were risk factors.

Risk factors for infection with CCHF

In the case-control study, we found that people living within 1 km of grazing fields for livestock were 18 times more likely to be CCHF case-patients than controls (ORM-H = 18, 95%CI = (3.2-∞); n = 12 (86%) cases and n = 27 (48%) controls lived < 1km) and people that identified ticks attached to their bodies during the effective exposure period were 9 times more likely to be CCHF case-patients than controls (ORM-H = 9.3, 95%CI = 1.9–46; n = 10 (71%) cases and n = 15 (27%) identified ticks attached to their bodies) shown in Table 2.

Table 2. Association between risk factors and Crimean-Congo haemorrhagic fever infection during July 2018 to January 2019 in Western and Central Uganda.

Risk factor during 14 days before illness onset Cases (%) Controls (%) Crude OR (95%CI) ORM-H (95%CI)
Household had grazing fields within 1km
    Yes
    No

12 (86)
2 (14)

27 (48)
29 (52)

6.4 (1.3–31)
Ref.

18 (3.2-∞)*
Ref.
Noticed a tick attached to their body
    Yes
    No

10 (71)
4 (29)

15 (27)
41 (73)

6.8 (1.9–25)
Ref.

9.3 (1.9–46)
Ref.
Had livestock within household
    Yes
    No

10 (71)
4 (29)

31 (55)
25 (45)

2.0 (0.56–7.2)
Ref.

2.5 (0.6–10)
Ref.
Livestock in household had ticks
    Yes
    No

7 (70)
3 (30)

16 (50)
16 (50)

2.3 (0.51–10)
Ref.

2.0 (0.35–11)
Ref.
Had livestock in neighbourhood
    Yes
    No

13 (93)
1 (7)

36 (64)
20 (36)

7.2 (0.88–59)
Ref.

n/a
Neighbourhood livestock had ticks
    Yes
    No

8 (80)
2 (20)

13 (48)
14 (52)

4.3 (0.77–24)
Ref.

8.3 (0.78–89)
Ref.
Took ticks off livestock
    Yes
    No

5 (36)
9 (64)

10 (18)
46 (82)

2.6 (0.7–9.3)
Ref.

2.7 (0.73–9.7)
Ref.
Interacted with livestock
    Yes
    No

10 (71)
4 (29)

27 (48)
29 (52)

2.7 (0.75–9.6)
Ref.

4.3 (0.86–21)
Ref.
Introduced new livestock to household
    Yes
    No

4 (40)
6 (60)

6 (19)
26 (81)

2.9 (0.62–13)
Ref.

5.3 (0.73–38)
Ref.
Drank milk
    Yes
    No

9 (64)
5 (36)

40 (71)
16 (29)

0.72 (0.21–2.5)
Ref.

0.67 (0.17–2.7)
Ref.
Drank raw milk
    Yes
    No

5 (36)
9 (64)

12 (21)
44 (79)

2.0 (0.57–7.2)
Ref.

5.0 (0.64–39)
Ref.
Drank macunde (fermented milk)
    Yes
    No

4 (29)
10 (71)

14 (25)
42 (75)

1.2 (0.32–4.4)
Ref.

1.3 (0.25–7.1)
Ref.

*analysed using exact conditional logistic regression

interacting with livestock involved herding, selling livestock, slaughtering, skinning and butchering carcasses, milking livestock or use of oxen to plough fields

Discussion

Human CCHF outbreaks in Uganda from mid-2018 to early 2019 were primarily associated with tick bites. This is a well-known risk factor and the findings are similar to those from previous CCHF outbreak investigations in Uganda [12,13] and globally [1720]. A single case-patient in our investigation likely contracted the illness from another case-patient; his symptoms were mild, which is known to be associated with person-to-person routes of exposure for CCHFv [21,22], and his degree of exposure to the case-patient and the timing of his illness onset make person-to-person transmission likely.

Reports of CCHF outbreaks in Uganda are becoming more frequent. From 2013 to 2017, eight outbreaks were confirmed. An additional two outbreaks (not described in this manuscript) occurred in early 2018. However, within just seven months during July 2018 to January 2019, 13 sporadic outbreaks were reported. It is unclear whether or not this is due to improved surveillance during this time period or a true increase in cases. In addition, an Ebola outbreak in the neighbouring Democratic Republic of Congo (DRC) was occurring during the same time period as this outbreak investigation [23], with the Ebola-affected area approximately 350km away from the Ugandan border of Mpondwe [23,24], and it is possible that the resulting heightened surveillance for VHF led to increased testing and diagnosis.

Currently, Uganda does not have a joint nationwide tick-control intervention or strategy despite past studies citing tick exposure as a risk factor for CCHF [25]. The choice to implement tick control measures in livestock is made individually, and at the cost of the livestock owner. However, individual tick control efforts will not be useful unless they are widely implemented. Having a grazing field near home was a strong independent risk factor for infection, likely because tick-infested livestock will sustain tick presence in grazing fields, even when one’s own livestock do not harbour ticks. Communal or even regional concerted tick control efforts may be warranted to fully control this issue.

Beyond the issues with heterogeneous use of tick control across communities, the lack of national tick control guidelines has resulted in indiscriminate use of acaricides (pesticides specially for ticks), which has led to increased resistance among ticks in Uganda [26]. There have been recent documented increases in tick resistance to acaricides, which may have led to an increasing tick population. A study on tick resistance to acaricides in Western and Central Uganda found that 13% of ticks tested were resistant to the common acaricide Amitraz (mostly in Western Uganda), 43% to organophosphate-synthetic pyrethroid co-formulation, and 90% to selected synthetic pyrethroids. No ticks died when exposed to synthetic pyrethroids, and approximately 60% had super-resistance. These super-resistant ticks were found in abattoirs in Gulu located in Northern Uganda, showing the geographic spread of resistance around the country [26]. Increases in resistance could lead to greater tick infestations on livestock and subsequent increases in human CCHFv infections; however, this remains speculative since these studies do not necessarily focus on Hyalomma ticks and further investigation would be needed to evaluate this.

Our investigations established CCHF outbreaks in 11 districts. Although the districts are geographically distinct from each other, most are located within the “cattle corridor” [27]. In the cattle corridor, livestock are raised and are frequently traded within Uganda. Movement and trade of infected livestock has been found to modify geographical areas at risk for CCHF outbreaks [5]. In our study, the case-patient from Mukono District who lived in an urban setting–normally without risk of tick exposure–may have been exposed to a tick on livestock that had been transported to the urban mosque. Livestock trading is not strictly controlled in Uganda in terms of inspection and issuing of trade permits; livestock are often transported across the country in trucks indiscriminately. This kind of movement can easily introduce CCHFv to new territories [28,29].

Preventing CCHF outbreaks is challenging due to absence of an effective vaccine, widespread presence of ticks, and the fact that CCHFv infection is asymptomatic in livestock. Risk for exposure is always present in communities where residents have close contact with livestock. For this reason, prevention efforts should be strengthened through awareness and education efforts with regards to reducing transmission risk and improving tick control in such communities.

Study limitations

A small number of persons [14] met the case definition however we matched each with four controls to add power to the study. We have no further information on tick species or whether livestock were infected because we could not perform any analysis on blood and tick samples collected from livestock within households due to resource constraints.

Conclusions, public health actions and recommendations

CCHF outbreaks in Uganda during 2018 and 2019 were sporadic, dispersed in multiple districts, and primarily associated with proximity to grazing fields and tick exposure. We educated affected communities on risk factors and prevention strategies for CCHFv transmission. The district rapid response teams were activated, including establishment of an emergency hotline for case reporting. Healthcare workers were trained in patient management, and infection control and isolation units were designated in general hospitals in the affected districts. No further cases have been confirmed in the villages that were sensitized as of August 2019.

CCHF is a zoonotic disease that affects humans however the infection does not cause disease in livestock. Nonetheless, there are other tick-borne infections that affect animal health. In Uganda, animal health is monitored under Ministry of Agriculture, Animal Industry, and Fisheries (MAAIF) while acaricides are regulated by National Drug Authority (NDA), an autonomous authority under Ministry of Health. We recommended that the Ministry of Health partners with MAAIF to develop joint nationwide tick control programs and strategies with shared responsibilities among the ministries through a One Health approach. We recommended that NDA improves its involvement in tick control strategies in Uganda by revising national regulations on acaricide distribution and use; developing strategies to reduce tick resistance to acaricides in the country through evidence-based use of acaricides supported by research [25]. More research studies should be conducted to identify acaricides to which ticks have developed resistance and the extent and geographical distribution that such ticks cover. We also recommended that a more community-based approach is used in tick control where community leaders mobilize the community towards communal tick-control efforts such as communal spraying livestock and rotation of acaricides used.

Acknowledgments

We acknowledge and appreciate the contributions of Mbarara Regional Referral Hospital and Nakivaale Health Center III towards investigation and response during the multiple CCHF outbreaks. We also acknowledge participation of the District Health Teams of the affected districts during the investigation. We also appreciate Uganda Virus Research Institute for support in sample transportation and prompt diagnosis of CCHF.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This project was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention Cooperative Agreement number GH001353–01 through Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the US Centers for Disease Control and Prevention, the Department of Health and Human Services, Makerere University School of Public Health, or the Ministry of Health. The staff of the funding body provided technical guidance in the design of the study, ethical clearance and collection, analysis, and interpretation of data and in writing the manuscript. Funding for the study was received through facilitation of field visits during investigations and general Fellowship activities not specific to the study.

References

  • 1.WHO. Crimean Congo Haemorrhagic Fever: Key facts 2017. Available from: https://www.afro.who.int/health-topics/crimean-congo-haemorrhagic-fever. [Google Scholar]
  • 2.Al-Abri SS, Al Abaidani I, Fazlalipour M, Mostafavi E, Leblebicioglu H, Pshenichnaya N, et al. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. International Journal of Infectious Diseases. 2017;58:82–9. 10.1016/j.ijid.2017.02.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.WHO. Crimean-Congo haemorrhagic fever World Health Organisation: World Health Oragnistaion; 2018. [updated 31 January 2013. Available from: http://www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever. [Google Scholar]
  • 4.Appannanavar SB, Mishra B. An Update on Crimean Congo Hemorrhagic Fever. J Glob Infect Dis. 2011;3(3):285–92. 10.4103/0974-777X.83537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Messina JP, Pigott DM, Golding N, Duda KA, Brownstein JS, Weiss DJ, et al. The global distribution of Crimean-Congo hemorrhagic fever. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015;109(8):503–13. 10.1093/trstmh/trv050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Telmadarraiy Z, Chinikar S, Vatandoost H, Faghihi F, Hosseini-Chegeni A. Vectors of Crimean Congo Hemorrhagic Fever Virus in Iran. Journal of arthropod-borne diseases. 2015;9(2):137–47. [PMC free article] [PubMed] [Google Scholar]
  • 7.Farhadpour F, Telmadarraiy Z, Chinikar S, Akbarzadeh K, Moemenbellah-Fard M, Faghihi F, et al. Molecular detection of Crimean–Congo haemorrhagic fever virus in ticks collected from infested livestock populations in a New Endemic Area, South of Iran. Tropical Medicine & International Health. 2016;21(3):340–7. [DOI] [PubMed] [Google Scholar]
  • 8.Naderi HR, Sheybani F, Bojdi A, Khosravi N, Mostafavi I. Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with very short incubation period. The American journal of tropical medicine and hygiene. 2013;88(3):469–71. 10.4269/ajtmh.2012.12-0337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Papa A, Tsergouli K, Tsioka K, Mirazimi A. Crimean-Congo Hemorrhagic Fever: Tick-Host-Virus Interactions. Frontiers in cellular and infection microbiology. 2017;7:213. 10.3389/fcimb.2017.00213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.WHO. Crimean-Congo haemorrhagic fever WHO website: WHO; 2019. [Available from: https://www.who.int/health-topics/crimean-congo-haemorrhagic-fever/-tab=tab_1. [Google Scholar]
  • 11.Shoemaker TR, Balinandi S, Tumusiime A, Nyakarahuka L, Lutwama J, Mbidde E, et al. Impact of enhanced viral haemorrhagic fever surveillance on outbreak detection and response in Uganda. The Lancet Infectious Diseases. 2018;18(4):373–5. 10.1016/S1473-3099(18)30164-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kizito S, Okello PE, Kwesiga B, Nyakarahuka L, Balinandi S, Mulei S, et al. Notes from the Field: Crimean-Congo Hemorrhagic Fever Outbreak—Central Uganda, August-September 2017. MMWR Morbidity and mortality weekly report. 2018;67(22):646–7. 10.15585/mmwr.mm6722a6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Balinandi S, Patel K, Ojwang J, Kyondo J, Mulei S, Tumusiime A, et al. Investigation of an isolated case of human Crimean-Congo hemorrhagic fever in Central Uganda, 2015. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2018;68:88–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.UBOS. National Population and Housing Census 2014. Uganda Bureau of Statistucs; 2014. [Google Scholar]
  • 15.Moses M, Stevens T, Bax G. GIS Data Ineroperability in Uganda. International Journal of Spatial Data Infrastructures Research. 2012;7:488–507. [Google Scholar]
  • 16.WHO. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland: World Health Organisation; 2014. p. 81–3. [Google Scholar]
  • 17.Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerging infectious diseases. 2004;10(8):1379–84. 10.3201/eid1008.030928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ozkurt Z, Kiki I, Erol S, Erdem F, Yılmaz N, Parlak M, et al. Crimean–Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. Journal of Infection. 2006;52(3):207–15. 10.1016/j.jinf.2005.05.003 [DOI] [PubMed] [Google Scholar]
  • 19.Chapman LE, Wilson ML, Hall DB, LeGuenno B, Dykstra EA, Ba K, et al. Risk factors for Crimean-Congo hemorrhagic fever in rural northern Senegal. Journal of Infectious Diseases. 1991;164(4):686–92. 10.1093/infdis/164.4.686 [DOI] [PubMed] [Google Scholar]
  • 20.Yagci-Caglayik D, Korukluoglu G, Uyar Y. Seroprevalence and risk factors of Crimean–Congo hemorrhagic fever in selected seven provinces in Turkey. Journal of medical virology. 2014;86(2):306–14. 10.1002/jmv.23699 [DOI] [PubMed] [Google Scholar]
  • 21.Pshenichnaya NY, Sydenko IS, Klinovaya EP, Romanova EB, Zhuravlev AS. Possible sexual transmission of Crimean-Congo hemorrhagic fever. International Journal of Infectious Diseases. 2016;45:109–11. 10.1016/j.ijid.2016.02.1008 [DOI] [PubMed] [Google Scholar]
  • 22.Izadi S, Salehi M, Holakouie-Naieni K, Chinikar S. The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J Infect Dis. 2008;61(6):494–6. [PubMed] [Google Scholar]
  • 23.Gostin L, Phelan A, Coutinho AG, Eccleston-Turner M, Erondu N, Filani O, et al. Ebola in the Democratic Republic of the Congo: time to sound a global alert? The Lancet. 2019. 10.1016/S0140-6736(19)30243-0 [DOI] [PubMed] [Google Scholar]
  • 24.Bedford JA, Jones G., Gercama T., I. Uganda-DRC cross-border dynamics. ReliefWeb; 2018. 15 December 2018. [Google Scholar]
  • 25.Vudriko P, Okwee-Acai J, Byaruhanga J, Tayebwa DS, Omara R, Muhindo JB, et al. Evidence-based tick acaricide resistance intervention strategy in Uganda: Concept and feedback of farmers and stakeholders. Ticks and Tick-borne Diseases. 2018;9(2):254–65. 10.1016/j.ttbdis.2017.09.011 [DOI] [PubMed] [Google Scholar]
  • 26.Vudriko P, Okwee-Acai J, Tayebwa DS, Byaruhanga J, Kakooza S, Wampande E, et al. Emergence of multi-acaricide resistant Rhipicephalus ticks and its implication on chemical tick control in Uganda. Parasites & vectors. 2016;9:4. 10.1186/s13071-015-1278-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nimusiima A, Basalirwa CP, Majaliwa JG, Kirya D, Twinomuhangi R. Predicting the Impacts of Climate Change Scenarios on Maize Yield in The Cattle Corridor of Central Uganda. Journal of Environmental and Agricultural Sciences.14:63–78. [Google Scholar]
  • 28.Mahzounieh M, Dincer E, Faraji A, Akin H, Akkutay AZ, Ozkul A. Relationship between Crimean-Congo hemorrhagic fever virus strains circulating in Iran and Turkey: possibilities for transborder transmission. Vector borne and zoonotic diseases (Larchmont, NY). 2012;12(9):782–5. 10.1089/vbz.2011.0928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zehender G, Ebranati E, Shkjezi R, Papa A, Luzzago C, Gabanelli E, et al. Bayesian Phylogeography of Crimean-Congo Hemorrhagic Fever Virus in Europe. PLOS ONE. 2013;8(11):e79663. 10.1371/journal.pone.0079663 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009213.r001

Decision Letter 0

Brian Bird, Aysegul Taylan Ozkan

11 Aug 2020

Dear MISS Mirembe,

Thank you very much for submitting your manuscript "Sporadic Outbreaks of Crimean-Congo Haemorrhagic Fever in Uganda, July 2018-January 2019" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

Dear Dr. Mirembe and co-authors, Thank you very much for your submission to PLoS NTD on CCHF in Uganda. Your manuscript was reviewed by two leading experts in the fields of epidemiology and CCHFV. Both reviewers felt that some re-examination of the interpretation of our findings was warranted before further consideration for publication. Please pay close attention to their helpful comments and suggestions. I look forward to receiving a revised manuscript at your earliest convenience. Please stay safe, healthy, and in good spirits during these challenging COVID times. Yours, Dr. Brian Bird - UCD Davis One Health Institute, Associate Editor PLoS NTD

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Brian Bird, DVM, ScM, PhD

Associate Editor

PLOS Neglected Tropical Diseases

Aysegul Taylan Ozkan

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Dear Dr. Mirembe and co-authors, Thank you very much for your submission to PLoS NTD on CCHF in Uganda. Your manuscript was reviewed by two leading experts in the fields of epidemiology and CCHFV. Both reviewers felt that some re-examination of the interpretation of our findings was warranted before further consideration for publication. Please pay close attention to their helpful comments and suggestions. I look forward to receiving a revised manuscript at your earliest convenience. Please stay safe, healthy, and in good spirits during these challenging COVID times. Yours, Dr. Brian Bird - UCD Davis One Health Institute, Associate Editor PLoS NTD

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The objectives are clear. The testable hypotheses could be better described. Is your goal to see if risk factors in Uganda are similar to known risk factors in other endemic countries? Or do do you want to know whether exposure was due to human contact, tick exposure or livestock exposure so that mitigation measures can be properly allocated?

A matched case-control study design is appropriate for this study.

Sample size: 14 confirmed cases is low, however given that a large geographic area was evaluated and a significant number of suspect cases (n=409) were explored, the methods were appropriate. I would like further information on how the 14 confirmed cases were identified. Were all 409 suspects tested and there were only 14 confirmed RT-PCR positives? How many medical facilities were included in this surveillance program? How were they distributed within districts? What kinds of facilites were they (referral hospitals, local medical clinics, etc.)?

Calculating attack rates don’t seem appropriate with such small case numbers and likely many missed cases. I suggest analyzing your data regarding age as an odds ratio.

I suggest, re-evaluated your stratification methods for calculation of your Mantel-Haenzel odds ratios so that each stratum has larger sample size numbers. Stratification into 14 categories (based on matched case-control subsets, isn’t going to give you large enough sample sizes for each strata). Try stratifying by age or sex and see if that significantly changes your adjusted values.

Reviewer #2: the methods are clearly described and appropriate for the study.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Methods for logistic and exact logistic regression models are described in the methods but I don’t see any results of this described.

I suggest the following sub-headings for results section: 1. Descriptive epidemiology of confirmed CCHF cases, 2. Risk factors for infection with CCHF

The description of results in the case-control portion of the study could be more clearly presented. I suggest presenting the significant risk factors first in a format that focuses on risk. For example, “The odds of living within 1 km of grazing fields for livestock were 18 times higher among CCHF case-patients than controls (ORMH = 18, CI=___; n = 12 (86%) cases and n = 27 (48%) controls lived < 1km).”

Table 1: 5th column title could be “Potential routes of exposure”. This column could be presented in more bullet point form than paragraphs. That would consolidate this table.

Was being within the cattle corridor a significant risk factor? I suggest adding this to your table.

Reviewer #2: The results are clearly presented and the tables are suitable for concise and clear presentation of the results.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusions are supported by the data presented. Limitations of the study could be further described.

The recommendations surrounding tick control are helpful and relevant for this topic and are specific to this region. I’m curious why butchering / slaughtering / handling livestock carcasses and bodily fluids was not investigated as potential risk factors? There are distinct differences with regard to virus exposure between rearing livestock and the act of butchering and it would have been interesting to see if there was a distinction between these two activities in this region. Could this analysis be added? This would help public health authorities to prioritize interventions around tick exposure as opposed to safe handling of livestock carcasses.

The public health relevance was thoroughly discussed.

Reviewer #2: Public health relevance is addressed in the study.

My main concern with this manuscript is that the authors have indicated the need to implement tick control as a method to reduce the burden of CCHFV infections and make reference to possible increased tick resistance due to acaricide control. However although increased tick control would be recommended nowhere in their manuscript do they actually mention that CCHFV is transmitted by ticks belonging to the genus Hyalomma, which are considered to be the principal vectors. although the virus has been isolated from some 30+ species of tick, the role of these ticks as vectors is not clear. In addition the paper they refer to for increased tick resistance was based on data mostly for Rhipicephalus species (no Hyalomma were identified in the paper). hence although the indiscriminate use of acaracides may have influenced hyalomma populations there is no evidence from the manuscript cited to support this. this needs to be made clearer in the manuscript.

what tick species occur in the districts investigated? was there any information on the tick species described in this study? if no information then please include this as a limitation of the study.

Line 251: the case living in an urban area may also have been exposed to infected blood during slaughter of animals as religious festivals and so this sentence regarding tick exposure is not justified and considering there was evidence of tick-bite.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Line 24 – 25 – Reword - >4 what? (days or symptoms?)

Line 27 – Check on distinction between using CCHF and CCHFV throughout. You test for the virus but diagnose the disease.

Line 35 – 36 – was this difference in attack rates statistically significant?

Line 46 – What is the One Health aspect of control you are recommending? Tick control for both the environment and animals? This could be clarified.

Line 66 – “caused by a tick-born virus in the genus Nairovirus, family Orthobunyaviridae”

LINE 80 – “other bodily secretions”

Line 93 – reference figure 1 when describing the “cattle corridor”

Line 109 – “…occurring between 1 July 2018-30 in a resident of 1 of the 11 affected districts.”

Line 118 – “We conducted a descriptive epidemiology investigation to collect information on symptoms, demographics, location and timing of infection and associated activities.”

Line 122 – “To identify potential risk factors for infection, we interviewed……”

Line 124 – 125 – What was the effective exposure period that you used?

Line 136 – what do you mean by “population statics”?

Line 137 – “significance was calculated…”

Line 145 – Were the non-confirmed suspect case-patients negative on PCR or not tested?

Line 190 – 193- If you’re going to state hypotheses or describe known risk factors for CCHF from other studies, this information would be better placed in the introduction.

Line 223 -224. This last sentence is redundant.

Reviewer #2: Lines 6 to 7: Please correct, CCHF is caused by Crimean-Congo hemorrhaguc fever orthonairovirus a member of the Orthonairovirus genus and the family Nairoviridae

Line 73: Crimean-Congo haemorrhagic fever orthonairovirus (CCHFV) is a tick-borne virus found in Africa, Asia, eastern Europe and the Balkans.

I suggest adding : The geographic distribution of the virus correlates with that of ticks belonging to the genus Hyalomma, which are considered to be the principal vectors.

Line 76-77: the authors state that The incubation period for CCHF in humans depends on viral dose, genetic factors and immune status of the host, and route of infection (6, 7). it is accepted that the incubation period does vary with source of infection, that is tick bite versus exposure to infected tissues, but the role of viral dose and genetic factors is not so clearly defined. I am unsure what is referred to when saying immune status influences incubation period.

Line 78: authors state that Incubation is typically 1-9 days following a tick bite, and 5-13 days following contact with infectious fluids. it would be more accurate to indicate that incubation period is usually 2 to 3 days following tick bite although occasionally longer the incubation period is typically short after tick bite.

Please provide references for all instances where previous cases in Uganda are referred to.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This was an important epidemiological investigation of CCHF cases in Uganda that explored several well-known risk factors for infection with the virus in endemic countries, in the specific context of Uganda. The finding that tick bites were the major risk factor for infection as opposed to direct contact with livestock has important implications for public health messaging and interventions in Uganda.

Reviewer #2: the authors have submitted a paper that will contribute to our knowledge of CCHF infections in Uganda and hence is an important paper but I suggest some of the limitations of the study especially with regard to the lack of information on tick species be considered.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009213.r003

Decision Letter 1

Brian Bird, Aysegul Taylan Ozkan

15 Dec 2020

Dear MISS Mirembe,

Thank you very much for submitting your manuscript "Sporadic Outbreaks of Crimean-Congo Haemorrhagic Fever in Uganda, July 2018-January 2019" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Dear Authors, Thank you for the hard work on your revision. One of the reviewers has a few more minor comments that when addressed will further enhance the readability and clarity of your manuscript. We look forward to your revised and updated manuscript. Yours, -Brian Bird, PLoS NTD Associate Editor; UC Davis One Health Institute

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Brian Bird, DVM, ScM, PhD

Associate Editor

PLOS Neglected Tropical Diseases

Aysegul Taylan Ozkan

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Dear Authors, Thank you for the hard work on your revision. One of the reviewers has a few more minor comments that when addressed will further enhance the readability and clarity of your manuscript. We look forward to your revised and updated manuscript. Yours, -Brian Bird, PLoS NTD Associate Editor; UC Davis One Health Institute

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Overall the methods were appropriate for the data and to address the stated objectives. There is a discrepancy between descriptions of the case-definition between the main text and the abstract. One states all cases were confirmed by PCR and the other says PCR or IgM serology. This is an important distinction that should be clarified. Including only cases that tested positive by PCR would be stronger.

"Exact conditional logistic regression was used with variables that failed to converge during stratification." I'm not following this part. There shouldn't have been model convergence issues with calculating M-H Odds ratios. Is this description referring to your method for calculating the crude Odds ratios that you report in the results? If so, I would state it like that.

The population is clearly described and appropriate for the hypothesis being tested. The number of confirmed cases is small but given the type of study, the analyses and the use of 4 matched controls per case was appropriate. There are no concerns about ethical or regulatory requirements being met.

Reviewer #2: The authors have addressed reviewer comments

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Table 2: The sample sizes for individual acaricides in the table is small and no statistics at the individual level are provided, so I would remove these. Frequency of spraying livestock also doesn't seem to fit as a "risk factor" for developing CCHF in this table because no analyses of them as risk factors are provided. For the "Butchering meat" and "Slaughtering animals" factors can those be categorized as something other than N/A's. Weighted correction methods such as the Haldane-Anscombe correction could be used to calculate odds ratios when one of the categories is 0. For some risk factors not all of the cases are represented (i.e. slaughtering animals only has data from 10 cases). Was data not collected for some of these cases on these topics?

Study Limitations: I don't think you need to state these. You did a nice risk factor study regardless of whether your original objectives were met and this section feels a bit like it comes out of the blue because it wasn't mentioned earlier as an objective of the study.

Reviewer #2: the authors have addressed previous comments

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: Conclusions are supported by the data presented. The conclusion section could take more of an active voice as you are making these recommendations to the people reading the paper in addition to the people you have already informed on the recommendations. The public health relevance is clearly addressed.

The study limitations could mention the small number of cases that met the case definition. The discussion of development of resistance to acaricides amid inconsistent use is interesting and highly relevant to future public health interventions. Perhaps a short discussion of recommendations for future research in this area, to identify specific acaricides in which ticks have developed resistance to in Uganda is worth mentioning.

Reviewer #2: the authors have addressed previous comments

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Throughout: double check the use of CCHF vs CCHFV to make sure you are referring to the disease or the pathogen the way intended

Line 27: should be "CCHFV"

Line 37: missing an "=" sign for P value

Line 45: I like that you are calling out the One Health approach here but it's a bit vague what the context is. Are you meaning that preventive measures for tick control should be taken for both livestock and humans to lessen human exposure to tick bites? A sentence of clarification would help here.

Line 70: "or from one human to another"

Line 71: the term "wild livestock" sounds contradictory; change to "domestic livestock and wild ungulates", or "wildlife"

Line 72: use CCHFV

Line 74: "important predictor of virus distribution"

Line 77: CCHFV

Line 80: CCHFV

Line 82: CCHFV

Line 83: should be "other bodily secretions".

Line 117: CCHFV

Line 119: CCHFV

Line 153: CCHFV-positive

Line 185: should be "did not report tick bites"

Table 1: Use periods at the end of each bullet or don't use them but be consistent throughout table.

Line 202: "In the case-control study, we found that people living within 1 km of grazing fields for livestock were 18 times more likely to be CCHF case-patients than controls"

Line 220: CCHFV

Line 261: change to "at risk for CCHF outbreaks".

Line 266: can use CCHF virus or CCHFV but be consistent throughout paper

Line 268: Use alternative word than "interrupting", such as "preventing"

Line 276: "similar strains of CCHFV"

Reviewer #2: no comment

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This research identifies the most common risk factors associated with CCHF outbreaks in Uganda which has implications for implementation of public health measures to prevent this disease. It's valuable to know that tick bites as opposed to exposure to bodily fluids from livestock appears to be the major driver of cases in Uganda. The case information is clearly presented. Table 2 could use some further consideration on what should be presented as a risk factor as described above.

Reviewer #2: no additional comments

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009213.r005

Decision Letter 2

Brian Bird, Aysegul Taylan Ozkan

5 Feb 2021

Dear MISS Mirembe,

We are pleased to inform you that your manuscript 'Sporadic Outbreaks of Crimean-Congo Haemorrhagic Fever in Uganda, July 2018-January 2019' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Brian Bird, DVM, ScM, PhD

Associate Editor

PLOS Neglected Tropical Diseases

Aysegul Taylan Ozkan

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

Dear Authors, Thank you for your submission to PLoS NTD and your subsequent hard work in responding to the reviewers comments and suggestions. I look forward to seeing your manuscript on-line to share your data on CCHF across Uganda. Yours, -Brian Bird; UC Davis One Health Institute, PLoS NTD Associate Editor

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009213.r006

Acceptance letter

Brian Bird, Aysegul Taylan Ozkan

1 Mar 2021

Dear MISS Mirembe,

We are delighted to inform you that your manuscript, "Sporadic Outbreaks of Crimean-Congo Haemorrhagic Fever in Uganda, July 2018-January 2019," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to reviewers.pdf

    Attachment

    Submitted filename: Response to Reviewers.doc

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES